SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-22-005301
Filing Date
2022-02-16
Accepted
2022-02-16 08:30:26
Documents
12
Period of Report
2022-02-15
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ANDA ljpc-8k_20220215.htm   iXBRL 8-K 35021
  Complete submission text file 0001564590-22-005301.txt   164039

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ljpc-20220215.xsd EX-101.SCH 5745
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ljpc-20220215_lab.xml EX-101.LAB 19431
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ljpc-20220215_pre.xml EX-101.PRE 11621
6 EXTRACTED XBRL INSTANCE DOCUMENT ljpc-8k_20220215_htm.xml XML 3553
Mailing Address 201 JONES ROAD, SUITE 400 WALTHAM MA 02451
Business Address 201 JONES ROAD, SUITE 400 WALTHAM MA 02451 617-715-3600
LA JOLLA PHARMACEUTICAL CO (Filer) CIK: 0000920465 (see all company filings)

IRS No.: 330361285 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36282 | Film No.: 22641588
SIC: 2836 Biological Products, (No Diagnostic Substances)